Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis

Marina G. Silveira, Ayako Suzuki, Keith Lindor

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) occurs with increased frequency in patients with primary biliary cirrhosis (PBC). Effectiveness of surveillance recommendations for HCC is controversial, and data are lacking in patients with PBC. In this study, we attempt to (1) establish the importance of surveillance for HCC in patients with PBC; (2) identify a target population of patients with PBC for HCC surveillance; and (3) propose surveillance recommendations for patients with PBC. We retrospectively identified 36 patients seen at the Mayo Clinic between 1976 and 2007 with a diagnosis of both PBC and HCC. Five patients (14%) were diagnosed incidentally, 17 patients comprised our surveillant population, and 14 patients were diagnosed outside a surveillance program. Patients in the surveillant population were more likely to undergo therapy (88% versus 43%; P = 0.01) and had improved survival (P = 0.002) compared with the nonsurveillant population. All cases of HCC except one were predicted to be at significant risk for HCC based on age, sex, evidence of portal hypertension, and history of blood transfusion using a previous predictive model. Conclusion: We established the importance of surveillance for HCC in patients with PBC. We demonstrated adequate performance of a predictive model and propose it should be refined and used to identify patients with PBC who should be screened for development of HCC. Further studies are needed so that optimal HCC surveillance recommendations in this population can be determined and included in the practice guidelines for PBC.

Original languageEnglish (US)
Pages (from-to)1149-1157
Number of pages9
JournalHepatology
Volume48
Issue number4
DOIs
StatePublished - Oct 2008
Externally publishedYes

Fingerprint

Biliary Liver Cirrhosis
Hepatocellular Carcinoma
Population
Health Services Needs and Demand
Portal Hypertension
Practice Guidelines
Blood Transfusion

ASJC Scopus subject areas

  • Hepatology
  • Medicine(all)

Cite this

Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis. / Silveira, Marina G.; Suzuki, Ayako; Lindor, Keith.

In: Hepatology, Vol. 48, No. 4, 10.2008, p. 1149-1157.

Research output: Contribution to journalArticle

Silveira, Marina G. ; Suzuki, Ayako ; Lindor, Keith. / Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis. In: Hepatology. 2008 ; Vol. 48, No. 4. pp. 1149-1157.
@article{3c654ef89a294e7c8d7f40975457197d,
title = "Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis",
abstract = "Hepatocellular carcinoma (HCC) occurs with increased frequency in patients with primary biliary cirrhosis (PBC). Effectiveness of surveillance recommendations for HCC is controversial, and data are lacking in patients with PBC. In this study, we attempt to (1) establish the importance of surveillance for HCC in patients with PBC; (2) identify a target population of patients with PBC for HCC surveillance; and (3) propose surveillance recommendations for patients with PBC. We retrospectively identified 36 patients seen at the Mayo Clinic between 1976 and 2007 with a diagnosis of both PBC and HCC. Five patients (14{\%}) were diagnosed incidentally, 17 patients comprised our surveillant population, and 14 patients were diagnosed outside a surveillance program. Patients in the surveillant population were more likely to undergo therapy (88{\%} versus 43{\%}; P = 0.01) and had improved survival (P = 0.002) compared with the nonsurveillant population. All cases of HCC except one were predicted to be at significant risk for HCC based on age, sex, evidence of portal hypertension, and history of blood transfusion using a previous predictive model. Conclusion: We established the importance of surveillance for HCC in patients with PBC. We demonstrated adequate performance of a predictive model and propose it should be refined and used to identify patients with PBC who should be screened for development of HCC. Further studies are needed so that optimal HCC surveillance recommendations in this population can be determined and included in the practice guidelines for PBC.",
author = "Silveira, {Marina G.} and Ayako Suzuki and Keith Lindor",
year = "2008",
month = "10",
doi = "10.1002/hep.22458",
language = "English (US)",
volume = "48",
pages = "1149--1157",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis

AU - Silveira, Marina G.

AU - Suzuki, Ayako

AU - Lindor, Keith

PY - 2008/10

Y1 - 2008/10

N2 - Hepatocellular carcinoma (HCC) occurs with increased frequency in patients with primary biliary cirrhosis (PBC). Effectiveness of surveillance recommendations for HCC is controversial, and data are lacking in patients with PBC. In this study, we attempt to (1) establish the importance of surveillance for HCC in patients with PBC; (2) identify a target population of patients with PBC for HCC surveillance; and (3) propose surveillance recommendations for patients with PBC. We retrospectively identified 36 patients seen at the Mayo Clinic between 1976 and 2007 with a diagnosis of both PBC and HCC. Five patients (14%) were diagnosed incidentally, 17 patients comprised our surveillant population, and 14 patients were diagnosed outside a surveillance program. Patients in the surveillant population were more likely to undergo therapy (88% versus 43%; P = 0.01) and had improved survival (P = 0.002) compared with the nonsurveillant population. All cases of HCC except one were predicted to be at significant risk for HCC based on age, sex, evidence of portal hypertension, and history of blood transfusion using a previous predictive model. Conclusion: We established the importance of surveillance for HCC in patients with PBC. We demonstrated adequate performance of a predictive model and propose it should be refined and used to identify patients with PBC who should be screened for development of HCC. Further studies are needed so that optimal HCC surveillance recommendations in this population can be determined and included in the practice guidelines for PBC.

AB - Hepatocellular carcinoma (HCC) occurs with increased frequency in patients with primary biliary cirrhosis (PBC). Effectiveness of surveillance recommendations for HCC is controversial, and data are lacking in patients with PBC. In this study, we attempt to (1) establish the importance of surveillance for HCC in patients with PBC; (2) identify a target population of patients with PBC for HCC surveillance; and (3) propose surveillance recommendations for patients with PBC. We retrospectively identified 36 patients seen at the Mayo Clinic between 1976 and 2007 with a diagnosis of both PBC and HCC. Five patients (14%) were diagnosed incidentally, 17 patients comprised our surveillant population, and 14 patients were diagnosed outside a surveillance program. Patients in the surveillant population were more likely to undergo therapy (88% versus 43%; P = 0.01) and had improved survival (P = 0.002) compared with the nonsurveillant population. All cases of HCC except one were predicted to be at significant risk for HCC based on age, sex, evidence of portal hypertension, and history of blood transfusion using a previous predictive model. Conclusion: We established the importance of surveillance for HCC in patients with PBC. We demonstrated adequate performance of a predictive model and propose it should be refined and used to identify patients with PBC who should be screened for development of HCC. Further studies are needed so that optimal HCC surveillance recommendations in this population can be determined and included in the practice guidelines for PBC.

UR - http://www.scopus.com/inward/record.url?scp=54449088795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54449088795&partnerID=8YFLogxK

U2 - 10.1002/hep.22458

DO - 10.1002/hep.22458

M3 - Article

VL - 48

SP - 1149

EP - 1157

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 4

ER -